About Us
Cimeio Therapeutics
Cimeio is a therapeutics company developing Shielded-Cell & Immunotherapy Pairs™ (SCIP), novel immunotherapies which have the potential to transform treatment of hematologic diseases. Cimeio develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in HSCs. These novel epitope edited variants maintain their function but are resistant to depletion when targeted by the paired immunotherapy which has high affinity for the wild-type version of these proteins.
These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. Shielded Cell and Immunotherapy Pairs and SCIP are trademarks of Cimeio Therapeutics, Inc.
Leadership
Lukas Jeker, MD/PhD
Founder, SVP Gene Editing
Nikita Sharma
Head of Business Development
Daniel Stark, PhD
Chief Manufacturing Officer
Stefanie Urlinger, PhD
Chief Scientific Officer
Lukas Jeker, MD/PhD
SVP Gene Editing
Nikita Sharma
Head of Business Development
Daniel Stark, PhD
Chief Manufacturing Officer
Stefanie Urlinger, PhD
Chief Scientific Officer
Scientific Advisory Board
Suneet Agarwal, MD, PhD
Assoc. Prof. Harvard Medical School
Jeff Bluestone, PhD
CEO, Sonoma Bio
Corey Cutler, MD, MPH, FRCPC
Assoc. Prof. Harvard Medical School
Fyodor Urnov, PhD, Chair
Prof. University of California Berkeley
Suneet Agarwal, MD, PhD
Jeff Bluestone, PhD
Corey Cutler, MD, MPH, FRCPC
Fyodor Urnov, PhD, Chair
Board of Directors
Markus Enzelberger, Ph.D.
Independent Director
Alexander Mayweg, Ph.D.
Chairman of the Board
Team
Julie Brault
Anna Camus
Valentin Do Sacramento
Laura Garcia Prat
Eva-Maria Grossjohann
Andreja Knezevic
Sophie Lackner
Frank Lehmann
Mathilde Testut
